IN2014CN02581A - - Google Patents

Info

Publication number
IN2014CN02581A
IN2014CN02581A IN2581CHN2014A IN2014CN02581A IN 2014CN02581 A IN2014CN02581 A IN 2014CN02581A IN 2581CHN2014 A IN2581CHN2014 A IN 2581CHN2014A IN 2014CN02581 A IN2014CN02581 A IN 2014CN02581A
Authority
IN
India
Prior art keywords
inducing
immune response
compositions
humoral
humoral immune
Prior art date
Application number
Other languages
English (en)
Inventor
Marc Mansour
Lisa Diana Macdonald
Genevieve Mary Weir
Leeladhar Sammatur
Kendall Sharp
Original Assignee
Immunovaccine Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovaccine Technologies Inc filed Critical Immunovaccine Technologies Inc
Publication of IN2014CN02581A publication Critical patent/IN2014CN02581A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
IN2581CHN2014 2011-10-06 2012-10-05 IN2014CN02581A (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161544020P 2011-10-06 2011-10-06
PCT/CA2012/050705 WO2013049941A1 (en) 2011-10-06 2012-10-05 Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof

Publications (1)

Publication Number Publication Date
IN2014CN02581A true IN2014CN02581A (de) 2015-08-07

Family

ID=48043153

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2581CHN2014 IN2014CN02581A (de) 2011-10-06 2012-10-05

Country Status (13)

Country Link
US (3) US10105435B2 (de)
EP (1) EP2763698B1 (de)
JP (2) JP6240077B2 (de)
CN (2) CN113876945A (de)
AU (1) AU2012321022B2 (de)
BR (1) BR112014007927B1 (de)
CA (1) CA2850857C (de)
ES (1) ES2855474T3 (de)
HK (1) HK1201044A1 (de)
IL (1) IL231888B (de)
IN (1) IN2014CN02581A (de)
SG (1) SG11201401177WA (de)
WO (1) WO2013049941A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
IN2014CN02581A (de) * 2011-10-06 2015-08-07 Immunovaccine Technologies Inc
ES2886999T3 (es) 2013-03-27 2021-12-21 Immunovaccine Technologies Inc Procedimiento para mejorar la eficacia de una vacuna de survivina en el tratamiento de cáncer
CN109893648A (zh) 2013-06-28 2019-06-18 奥克兰联合服务有限公司 氨基酸缀合物和肽缀合物及缀合方法
AU2014292926B2 (en) 2013-07-25 2020-03-05 Exicure Operating Company Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
MX2016007287A (es) 2013-12-03 2017-05-03 Univ Northwestern Particulas liposomales, metodos para elaborarlas y sus usos.
US20170035880A1 (en) * 2014-04-23 2017-02-09 University Of Florida Research Foundation, Incorporated Lipoteichoic acid from lactobacilli as a potent immune stimulatory adjuvant for vaccine development
PL3164113T3 (pl) 2014-06-04 2019-09-30 Exicure, Inc. Wielowartościowe dostarczanie modulatorów immunologicznych w liposomowych kolistych kwasach nukleinowych do zastosowań profilaktycznych lub terapeutycznych
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
JP2018505152A (ja) 2014-12-23 2018-02-22 アン ブリンブル マーガレット アミノ酸複合体及びペプチド複合体ならびにそれらの使用
JP2018509384A (ja) 2015-01-06 2018-04-05 イミューノヴァクシーン テクノロジーズ インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． リピドａ模倣体、調製方法、及びその使用
ES2900757T3 (es) 2015-02-10 2022-03-18 Ohio State Innovation Foundation Plataformas de células B activadas por clamidia y procedimientos de las mismas
CN106606775A (zh) * 2015-10-27 2017-05-03 格里菲斯大学 脂质体a群链球菌疫苗
JP7086000B2 (ja) 2015-11-10 2022-06-17 オハイオ・ステート・イノヴェーション・ファウンデーション 体液性親和性の加速に関する方法及び組成物
US11160861B2 (en) 2015-11-18 2021-11-02 Immunovaccine Technologies Inc. Adjuvanting systems and water-free vaccine compositions comprising a polyI:C polynucleotide adjuvant and a lipid-based adjuvant
CN105483076B (zh) * 2015-12-23 2019-01-25 中国科学院生物物理研究所 一种脂肪体的制备方法及其应用
EP3419962A4 (de) 2016-02-26 2020-03-11 Auckland Uniservices Limited Aminosäure- und peptidkonjugate und konjugationsverfahren
WO2017190242A1 (en) 2016-05-04 2017-11-09 Immunovaccine Technologies Inc. Vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier, and methods of use thereof
US11266602B2 (en) * 2016-05-16 2022-03-08 Infectious Disease Research Institute PEGylated liposomes and methods of use
EP3485002A4 (de) 2016-07-13 2020-07-29 Ohio State Innovation Foundation Plattformen und verfahren zur optimierung der host-antigen-darstellung sowie host-antitumor- und antipathogen-immunität
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
CA3038155A1 (en) 2016-09-27 2018-04-05 Immunovaccine Technologies Inc. Methods of using low dose volume b-cell epitope compositions for inducing an antibody immune response in human subjects
WO2018176099A1 (en) * 2017-03-31 2018-10-04 Ena Therapeutics Pty Ltd Treatment of respiratory infection with a tlr2 agonist
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)
EP3651733A4 (de) * 2017-07-10 2021-04-07 ImmunoVaccine Technologies Inc. Pharmazeutische zusammensetzungen, verfahren zur herstellung unter verwendung von lipidvesikelteilchen mit definierter grösse und verwendungen davon
KR20200028997A (ko) 2017-07-13 2020-03-17 노오쓰웨스턴 유니버시티 올리고뉴클레오타이드-작용화된 금속-유기 프레임워크 나노입자를 제조하는 일반적이고 직접적인 방법
KR102098097B1 (ko) * 2017-08-16 2020-05-26 주식회사 차백신연구소 리포펩티드가 삽입된 리포좀을 유효성분으로 포함하는 백신 아쥬반트 및 이의 용도
EP3727437A4 (de) * 2017-12-19 2021-09-08 The Governors of the University of Alberta Clostridium-perfringens-oberflächenglycane und ihre verwendung
CN109991422A (zh) * 2017-12-29 2019-07-09 复旦大学 基于特异抗血清的棕榈酰化修饰蛋白质的检测方法
US20220072023A1 (en) * 2018-07-12 2022-03-10 The Regents Of The University Of Michigan Compositions and methods for metal containing formulations capable of modulating immune response
US20220047698A1 (en) * 2018-10-26 2022-02-17 Alberta Research Chemicals Inc. Synthetic innate immune receptor ligands and uses thereof
JP2022539091A (ja) * 2019-06-26 2022-09-07 アクセリア オンコロジー ピーティーワイ リミテッド 新規な分子
AU2020340468A1 (en) * 2019-09-04 2022-03-24 Axelia Oncology Pty Ltd Cancer immunotherapy
JP2022546807A (ja) * 2019-09-04 2022-11-09 アクセリア オンコロジー ピーティーワイ リミテッド 癌の治療
US20220280631A1 (en) * 2021-03-07 2022-09-08 Henry J. Smith Viral pandemic vaccine
CN113181353B (zh) * 2021-04-09 2022-12-13 华中师范大学 一种抗病毒疫苗分子及其制备方法与应用

Family Cites Families (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3906092A (en) 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
GB2134869A (en) 1983-02-15 1984-08-22 Squibb & Sons Inc Method of preparing liposomes and products produced thereby
US4610868A (en) 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5897873A (en) 1984-04-12 1999-04-27 The Liposome Company, Inc. Affinity associated vaccine
US4803070A (en) 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4806350A (en) 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
US5084269A (en) 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US6093406A (en) 1988-06-02 2000-07-25 The United States Of America As Represented By The Secretary Of The Army Vaccine for induction of immunity to malaria
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
US5015476A (en) 1989-08-11 1991-05-14 Paravax, Inc. Immunization implant and method
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
IE904098A1 (en) 1989-11-13 1991-05-22 Nova Pharm Corp Lipospheres for controlled delivery of substances
US5091188A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
CA2082155C (en) 1990-05-29 2008-04-15 Krishnaswamy I. Dayalu Swine pneumonia vaccine and method of preparation
US5709879A (en) 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
ES2138588T3 (es) 1990-06-29 2000-01-16 Chiron Corp Composiciones de vacunas que contienen liposomas.
DE69131992T2 (de) 1990-12-12 2000-06-29 Univ Queensland St Lucia Papillomavirusuntereinheit-impfstoff
CA2072249C (en) 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
SK13494A3 (en) 1991-08-13 1994-09-07 Biotech Australia Pty Ltd Immunostimulation
US6037135A (en) 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
KR950700083A (ko) 1992-03-03 1995-01-16 스즈키 다다시 경구용 백신(oral vaccine)
US5855894A (en) 1992-03-30 1999-01-05 Pfizer Inc. Pasteurella haemolytica type A-1 bacterin-toxoid vaccine
USRE37224E1 (en) 1992-06-05 2001-06-12 Dalhousie University Method to prevent fertilization in mammals by administering a single dose of zona pellucida derived antigens, liposome and adjuvant
US5736141A (en) 1992-06-05 1998-04-07 Dalhousie University Method to prevent fertilization in mammals by administering a single dose of zona pellucida derived antigens, liposome and Freund's adjuvant
WO1993025231A1 (en) 1992-06-05 1993-12-23 Dalhousie University Use of zona pellucida glycoproteins for immunocontraception
SI9300468A (en) 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
US5820879A (en) 1993-02-12 1998-10-13 Access Pharmaceuticals, Inc. Method of delivering a lipid-coated condensed-phase microparticle composition
JPH06247842A (ja) 1993-02-23 1994-09-06 Green Cross Corp:The リポソーム組成物の製造方法
WO1995004542A1 (en) 1993-08-06 1995-02-16 Cytel Corporation Cloning and characterization of the complete mage-1 gene
JP3836874B2 (ja) 1994-02-24 2006-10-25 ノババックス インコーポレイテッド 免疫アジュバントとして少ラメラ脂質小胞を含むワクチン
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
JP3872813B2 (ja) 1994-05-18 2007-01-24 エス．ピー．アイ． シンセティック ペプチデス インコーポレイテッド ヘテロダイマーポリペプチド免疫原キャリア組成物および方法
US5688772A (en) 1994-08-01 1997-11-18 University Of Saskatchewan Quinoa saponin compositions and methods of use
US5637300A (en) 1994-08-03 1997-06-10 Dunbar; Bonnie S. Contraceptive vaccine comprising a glycosylated 55 kD zona pellucida protein immunogen and method of use of the same in contraception
FR2726764B1 (fr) 1994-11-14 1997-01-31 Pasteur Merieux Serums Vacc Adjuvant pour composition vaccinale
GB9422990D0 (en) 1994-11-15 1995-01-04 Cortecs Ltd Immunogenic compositions
FR2732895B1 (fr) 1995-04-11 1997-05-16 Pasteur Merieux Serums Vacc Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
US6846489B1 (en) 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
US5705151A (en) 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
WO1996040066A1 (en) 1995-06-07 1996-12-19 The Governors Of The University Of Alberta A METHOD FOR ELICITING A Th1-SPECIFIC IMMUNE RESPONSE
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US7019112B1 (en) 1996-03-19 2006-03-28 University Of Virginia Patent Foundation Peptides recognized by melanoma-specific A1-, A2- and A3-restricted cytoxic lymphocytes, and uses therefor
AU728221B2 (en) 1996-06-05 2001-01-04 Ashmont Holdings Limited Injectable compositions
US5919480A (en) 1996-06-24 1999-07-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal influenza vaccine composition and method
AR013829A1 (es) 1996-07-12 2001-01-31 Baxter Int Un dispositivo medico para suministrar cantidades volumetricas de un primer y un segundo fluido, bioquimicamente reactivos, y metodo para suministrarfibrina a una superficie con dicho dispositivo
US6284267B1 (en) 1996-08-14 2001-09-04 Nutrimed Biotech Amphiphilic materials and liposome formulations thereof
US5910306A (en) 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
CA2203843C (en) 1997-04-28 2013-07-23 Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence Liposome-encapsulated poly iclc
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
AU8053898A (en) 1997-05-28 1998-12-30 Jenner Biotherapies, Inc. Immunogenic compositions
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
JP2001513982A (ja) 1997-08-29 2001-09-11 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド フォリスタチン−３
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
AUPP060097A0 (en) 1997-11-28 1998-01-08 Commonwealth Scientific And Industrial Research Organisation Adjuvant system for enhanced response
ATE215385T1 (de) 1997-12-16 2002-04-15 Chiron Corp Verwendung von mikropartikeln mit submikron öl/wasser emulsionen
EP1067956B1 (de) 1998-04-03 2007-03-14 University Of Iowa Research Foundation Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
SE9801288D0 (sv) 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and metod of production
US6472375B1 (en) 1998-04-16 2002-10-29 John Wayne Cancer Institute DNA vaccine and methods for its use
US6632447B1 (en) 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
KR100682154B1 (ko) 1998-05-07 2007-02-12 코릭사 코포레이션 아쥬번트 조성물 및 그의 사용방법
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
AU768002B2 (en) 1998-06-15 2003-11-27 Oncoquest Inc. Immunotherapeutic composition and method for the treatment of prostate cancer
WO2000000178A1 (fr) 1998-06-30 2000-01-06 Rohto Pharmaceutical Co., Ltd. Compositions contenant des liposomes et/ou des emulsions et leur procede de preparation
FR2781160B1 (fr) 1998-07-03 2000-08-18 Pasteur Merieux Serums Vacc Utilisation d'un compose amphipathique pour adjuver un vaccin sous-unitaire
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US7087236B1 (en) 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
US20050084524A1 (en) 1998-09-30 2005-04-21 Alza Corporation Method for potentiating activity of a chemotherapeutic drug
US6787154B2 (en) 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
EP1140151A2 (de) 1998-12-22 2001-10-10 Dalhousie University Zusammensetzungen und methode zur verminderung oder reduzierung der fertilität bei fisch und geflügel
US6790457B1 (en) 1998-12-22 2004-09-14 Dalhousie University Compositions and methods for reducing or preventing fertilization in fish and birds
AU769539B2 (en) 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
EE200100597A (et) 1999-05-13 2003-02-17 American Cyanamid Company Antigeenne kompositsioon kombinatsioonis adjuvantidega ning meetod selle toimetõhususe suurendamiseks
US6670195B1 (en) 1999-05-26 2003-12-30 New York University Mutant genes in Familial British Dementia and Familial Danish Dementia
IL146567A0 (en) 1999-06-04 2002-07-25 Skyepharma Inc Oil-core particles containing a hydrophobic core material and hydrophobic drug and method for the preparation thereof
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
AU7877900A (en) 1999-10-13 2001-04-23 Chiron Corporation Method of obtaining cellular immune responses from proteins
US6605696B1 (en) 1999-10-22 2003-08-12 Pfizer, Inc. Lawsonia intracellularis proteins, and related methods and materials
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US6602510B1 (en) 2000-04-05 2003-08-05 Epimmune Inc. HLA class I A2 tumor associated antigen peptides and vaccine compositions
WO2001070663A2 (en) 2000-03-17 2001-09-27 Corixa Corporation Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
US6228648B1 (en) 2000-03-17 2001-05-08 Isis Pharmaceuticals, Inc. Antisense modulation of ADAM10 expression
US7449557B2 (en) 2000-06-02 2008-11-11 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
JP4164361B2 (ja) * 2000-11-07 2008-10-15 イムノワクチン テクノロジーズ インコーポレーテッド 増強した免疫応答を有するワクチン、およびその調製方法
ATE396707T1 (de) 2000-12-01 2008-06-15 Biomira Inc Herstellung grosser liposome durch infusion in peg
NZ526326A (en) 2000-12-08 2006-09-29 Academisch Ziekenhuis Leiden A CTL epitope petide of 22-45 amino acid residues for inducing and/or enhancing an antigen-specific T-cell response
WO2002053106A2 (en) 2001-01-05 2002-07-11 Joslin Diabetes Center, Inc. Autoantigen composition
US6497896B2 (en) 2001-02-12 2002-12-24 Supergen, Inc. Method for administering camptothecins via injection of a pharmaceutical composition comprising microdroplets containing a camptothecin
CN1168740C (zh) 2001-04-04 2004-09-29 上海美恩生物技术有限公司 细胞因子基因修饰的抗原提呈细胞/肿瘤细胞偶联物、其制法和用途
US6676958B2 (en) 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
EP1410806A4 (de) 2001-07-25 2007-07-04 Mitsubishi Pharma Corp Mittel zur behandlung von brustkrebs
EP2191845A1 (de) 2001-07-31 2010-06-02 University of Washington Immunologisch bedeutende Herpes-simplex-virus-antigene und Verfahren für ihre Verwendung
US6517816B1 (en) 2001-12-26 2003-02-11 Avon Products, Inc. Sunscreen emulsion composition and method of use
US7056515B2 (en) 2002-02-08 2006-06-06 Immunovaccine Technologies Inc. Antigens for immunocontraception
AU2003244428A1 (en) 2002-02-08 2003-09-02 Immunovaccine Technologies Inc. Antigens for immunocontraception
US7569021B2 (en) 2002-03-21 2009-08-04 Jolife Ab Rigid support structure on two legs for CPR
US20040101534A1 (en) 2002-06-25 2004-05-27 Diamond Don J. Adjuvant-free peptide vaccine
US20040213837A1 (en) 2002-08-05 2004-10-28 Sankaram Mantripragada Oil-core compositions for the sustained release of hydrophobic drugs
WO2004017944A1 (en) 2002-08-23 2004-03-04 Neopharm, Inc. Liposomal gemcitabine compositions for better drug delivery
EP1393720A1 (de) 2002-08-27 2004-03-03 Universiteit Utrecht Vesikel enthaltend Corticosteroide zur Behandlung von Krebs
DE10249401A1 (de) 2002-10-23 2004-05-13 Bernina Biosystems Gmbh Liposomen formende Zusammensetzung
US20050158375A1 (en) 2002-11-15 2005-07-21 Toshikiro Kimura Pharmaceutical composition containing liposomes for treating cancer
EP1583548A4 (de) 2002-12-10 2007-10-17 Epimmune Inc Hla-a1, a2 -a3,-a24,-b7 und -b44tumor-assoziierte antigenpeptide und zusammensetzungen
DK1992635T3 (da) 2002-12-23 2012-03-05 Dynavax Tech Corp Oligonukleotider med immunstimulatorisk sekvens og fremgangsmåder til anvendelse af disse
AU2003299994A1 (en) 2002-12-27 2004-07-29 Chiron Corporation Immunogenic compositions containing phospholpid
WO2004089981A2 (en) 2003-04-02 2004-10-21 Board Of Regents, The University Of Texas System Antitumor effect of mutant bik
SI1613346T1 (sl) 2003-04-04 2013-02-28 Pah Usa 15 Llc Mikrofluidizirane emulzije olja v vodi in sestava cepiv
SI1620456T1 (sl) 2003-04-18 2014-05-30 Biotech Synergy, Inc. Hla-a2 s tumorjem povezan antigen peptidov in sestavki
US20050002999A1 (en) 2003-06-04 2005-01-06 Rahul Mehta Long-circulating liposomal compositions
US20050013812A1 (en) 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
JP2007504149A (ja) 2003-08-26 2007-03-01 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 抗癌ワクチン
US20050220781A1 (en) 2003-09-04 2005-10-06 Duen-Hwa Yan IFIX, a novel HIN-200 protein, for cancer therapy
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
GB0323965D0 (en) 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
US20050266066A1 (en) 2003-10-20 2005-12-01 Nof Corporation Phospholipid membrane preparation
CA2542804A1 (en) 2003-10-24 2005-05-06 Alza Corporation Preparation of lipid particles
ATE434431T1 (de) 2003-11-14 2009-07-15 Het Nl Kanker I The Netherland Pharmazeutische formulierungen mit kurzketten- sphingolipiden und ihre verwendung
EP1732598A4 (de) 2003-12-31 2009-08-26 Pharmexa Inc Auslösung von zellulären immunantworten gegen den humanen papillovirus unter verwendung von peptid und nucleinsäure-zusammensetzungen
WO2005072777A2 (en) 2004-01-28 2005-08-11 Curix Aps Conjugates of amyloid proteins as vaccines for amyloid-related diseases
CN1997745A (zh) 2004-04-02 2007-07-11 得克萨斯州大学系统董事会 癌症特异性启动子
KR101143060B1 (ko) 2004-04-05 2012-05-08 화이자 프로덕츠 인코포레이티드 미세유체화된 수중유 유화액 및 백신 조성물
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
AU2005251691A1 (en) 2004-05-17 2005-12-22 Tekmira Pharmaceuticals Corporation Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
US20060120997A1 (en) 2004-10-29 2006-06-08 Biomune, Inc. Cancer therapeutic compositions
US8337815B2 (en) 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
DK1850832T3 (en) 2005-02-07 2015-04-13 Lipotek Pty Ltd adjuvanting
WO2006084319A1 (en) 2005-02-08 2006-08-17 The Council Of The Queensland Institute Of Medical Research Immunogenic molecules
US8895717B2 (en) 2005-04-15 2014-11-25 The Board Of Regents Of The University Of Texas System Delivery of siRNA by neutral lipid compositions
US20060275777A1 (en) 2005-06-03 2006-12-07 Waelti Ernst R Novel strategies for protein vaccines
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
WO2007022152A2 (en) 2005-08-15 2007-02-22 The Research Foundation Of State University Of New York Lipid nano particulates containing antigens as cancer vaccines
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
US7943147B2 (en) 2005-12-07 2011-05-17 Hemispherx Biopharma dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
AR058592A1 (es) 2005-12-22 2008-02-13 Glaxosmithkline Biolog Sa Vacuna
ATE485305T1 (de) 2006-02-24 2010-11-15 Us Gov Health & Human Serv Immunogene peptide und verwendungsverfahren dafür
EP1991204A2 (de) 2006-02-24 2008-11-19 Novartis AG Mikropartikel mit biologisch abbaubarem polymer und kationischem polysaccharid zur verwendung für immunogene zusammensetzungen
BRPI0708865A8 (pt) 2006-03-14 2019-01-22 Univ Oregon Health & Science métodos para produzir uma resposta imune à tuberculose
WO2007117469A2 (en) 2006-03-30 2007-10-18 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
US20080014217A1 (en) 2006-07-17 2008-01-17 Emmanuel Jules Hanon Influenza vaccine
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
US20090032666A1 (en) 2007-07-31 2009-02-05 Chun Fu Kuo Mouse pad
CN106310293A (zh) 2007-09-27 2017-01-11 免疫疫苗技术有限公司 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
BRPI0817484B1 (pt) * 2007-10-03 2021-08-17 Immunovaccine Technologies Inc Composição de vacina sem água, processo de produção e o uso dos mesmos
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
KR100900837B1 (ko) * 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물
JP5715051B2 (ja) 2008-06-05 2015-05-07 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． リポソーム、抗原、ポリヌクレオチド及び疎水性物質の連続相を含む担体を含む組成物
IN2014CN02581A (de) * 2011-10-06 2015-08-07 Immunovaccine Technologies Inc

Also Published As

Publication number Publication date
AU2012321022B2 (en) 2017-03-23
US20140234404A1 (en) 2014-08-21
EP2763698B1 (de) 2020-12-02
US10105435B2 (en) 2018-10-23
WO2013049941A1 (en) 2013-04-11
CN103998058A (zh) 2014-08-20
HK1201044A1 (en) 2015-10-23
CN103998058B (zh) 2021-11-05
JP2014528955A (ja) 2014-10-30
EP2763698A1 (de) 2014-08-13
BR112014007927A2 (pt) 2017-04-11
US20190142928A1 (en) 2019-05-16
US11077184B2 (en) 2021-08-03
CN113876945A (zh) 2022-01-04
JP2018008964A (ja) 2018-01-18
JP6625587B2 (ja) 2019-12-25
CA2850857C (en) 2022-07-26
SG11201401177WA (en) 2014-04-28
IL231888A0 (en) 2014-05-28
BR112014007927B1 (pt) 2021-04-13
EP2763698A4 (de) 2015-08-05
JP6240077B2 (ja) 2017-11-29
CA2850857A1 (en) 2013-04-11
AU2012321022A1 (en) 2014-04-17
ES2855474T3 (es) 2021-09-23
IL231888B (en) 2018-02-28
US20210308252A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
IN2014CN02581A (de)
MX2022003698A (es) Composiciones de nanoparticulas y metodos para inmunoterapia.
TN2014000206A1 (en) Antibody molecules having specificity for human ox40
PH12014502797A1 (en) Immunoconjugates comprising anti-cd22 antibodies
MX2020011696A (es) Formulacion arn para inmunoterapia.
MX2019010336A (es) Metodos para aumentar la eficacia de la terapia contra el cancer con receptor 1 de folato (folr1).
MX2019009654A (es) Anticuerpos e inmunoconjugados del receptor 1 de folato y usos de los mismos.
TW201129382A (en) Antibody formulation and therapeutic regimens
GB2505857A (en) Vaccine adjuvant composition comprising inulin particles
MX2012013731A (es) Vacunas que comprenden colesterol y cpg como moleculas portadoras-adyuvantes unicas.
IN2015DN00263A (de)
HK1201154A1 (en) Combination therapy using anti-cd20 antibody and human il-15 cd20 il-15
UA111738C2 (uk) Спосіб активної клітинної імунотерапії раку шляхом застосування пухлинних клітин, знищених за допомогою високого гідростатичного тиску, і дендритних клітин
IL231926A0 (en) Apoptosis-inducing factors for the treatment of cancer and immune and autoimmune diseases
MX349321B (es) Terapia combinada.
IN2014DN09717A (de)
MX2015017959A (es) Composiciones y metodos para inmunoterapia.
MA37749A1 (fr) Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine
MX350096B (es) Preservación asistida con vacío de productos biológicos, en particular de vacunas.
IN2015KN00449A (de)
PH12015502844B1 (en) Mammalian milk osteopontin for enhancing immune responsiveness
IN2014CN00547A (de)
EP2879705A4 (de) Peptidimpfstoffe auf basis der egfrviii-sequenz zur behandlung von tumoren
TH137287B (th) สารชักนำอะพอพโทซิสสำหรับการรักษามะเร็งและโรคทางภูมิคุ้มกันและภูมิต้าน ตนเอง (Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases)